INTERNATIONAL BUSINESS MACHINES CORPORATION (20240296929). PRECISION COMBINATION THERAPY USING TUMOR CLONE RESPONSE PREDICTION FROM CELL DATA simplified abstract
Contents
PRECISION COMBINATION THERAPY USING TUMOR CLONE RESPONSE PREDICTION FROM CELL DATA
Organization Name
INTERNATIONAL BUSINESS MACHINES CORPORATION
Inventor(s)
Filippo Utro of Pleasantville NY (US)
Kahn Rhrissorrakrai of Woodside NY (US)
Laxmi Parida of Mohegan Lake NY (US)
Chaya Levovitz of New York NY (US)
PRECISION COMBINATION THERAPY USING TUMOR CLONE RESPONSE PREDICTION FROM CELL DATA - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240296929 titled 'PRECISION COMBINATION THERAPY USING TUMOR CLONE RESPONSE PREDICTION FROM CELL DATA
The abstract describes the use of an AI platform to develop a combination therapy for a patient with a tumor that has produced clones, targeting resistant and evolved clones.
- The combination therapy includes at least two perturbations to target clones that have escaped therapeutic intervention.
- The AI platform is trained with perturbation data from a cell line similar to the clone of interest.
- The platform predicts how the clone will respond to perturbations and ranks the responses.
- The cell line used for training can be an existing cell line or a synthetic one generated by the AI platform.
- The AI platform may utilize machine learning, deep learning, artificial neural networks, convolution neural networks, and generative adversarial networks.
Potential Applications: - Personalized medicine for cancer treatment - Development of targeted therapies for other diseases with resistant clones
Problems Solved: - Targeting resistant and evolved clones in tumors - Improving treatment outcomes for patients with complex tumors
Benefits: - Increased effectiveness of cancer treatments - Reduced likelihood of tumor recurrence - Enhanced patient outcomes and quality of life
Commercial Applications: Title: AI-Powered Combination Therapy Development for Cancer Treatment This technology can be used in pharmaceutical companies for drug development, in oncology clinics for personalized treatment plans, and in research institutions for studying tumor evolution and resistance mechanisms.
Prior Art: Researchers can explore databases of cancer treatment studies, AI applications in drug development, and personalized medicine technologies for related prior art.
Frequently Updated Research: Stay updated on advancements in AI-driven cancer therapies, personalized medicine approaches, and tumor evolution studies for the latest research in this field.
Questions about AI-Powered Combination Therapy Development for Cancer Treatment: 1. How does the AI platform determine the most effective perturbations for targeting tumor clones? 2. What are the potential challenges in implementing personalized combination therapies based on AI predictions?
Original Abstract Submitted
an ai platform is used for developing a combination therapy for a patient afflicted with a tumor that has produced clones. the combination therapy, which includes at least two perturbations, is capable of targeting clones (including subclones) that have escaped therapeutic intervention due to resistance and/or evolution. the ai platform is trained with perturbation data obtained from at least one cell line that has similar characteristics to a clone of interest. the trained ai platform predicts how the clone of interest will respond to perturbations and ranks the perturbation responses from highest to lowest. the at least one cell line may be an existing cell line from a well-established database or a synthetic cell line generated by the ai platform. the ai platform may include one or more of a machine learning platform, a deep learning platform, an artificial neural network (ann), a convolution neural network (cnn), and a generative adversarial network (gan).
